Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;104(5):599-603.
doi: 10.1111/cas.12130. Epub 2013 Mar 29.

Locoregional recurrence of pT3N0M0 breast cancer after mastectomy is not higher than that of pT1-2N0M0: an analysis for radiotherapy

Jia-Yuan Sun  1 , San-Gang Wu, Sheng Li, Feng-Yan Li, Wen-Fen Chen, Qin Lin, Zhen-Yu He
Affiliations

Locoregional recurrence of pT3N0M0 breast cancer after mastectomy is not higher than that of pT1-2N0M0: an analysis for radiotherapy

Jia-Yuan Sun et al. Cancer Sci. 2013 May.

Abstract

The purpose of this study was to investigate the value of post-operative radiotherapy in the treatment of pT3N0M0 breast cancer after mastectomy. We analyzed the clinical data of 1390 patients with pT1-3N0M0 breast cancer who were admitted and treated from 1998 to 2007 at the Sun Yat-sen University Cancer Center. All patients underwent mastectomy and did not receive radiotherapy. The locoregional recurrence-free survival, distant metastasis-free survival and overall survival of different T stages of breast cancer were compared. The median follow-up duration was 72 months. The 10-year locoregional recurrence-free survival patients with pT1N0, pT2N0 and pT3N0 breast cancers were 95.3, 91.9 and 93.6%, respectively (χ(2) = 2.550, P = 0.279). The 10-year distant metastasis-free survival rates of patients with pT1N0, pT2N0 and pT3N0 breast cancers were 88.1%, 81.0% and 78.4%, respectively (χ(2) = 8.254, P = 0.016). The 10-year overall survival rates of patients with pT1N0, pT2N0 and pT3N0 breast cancers were 91.9%, 83.5% and 73.0%, respectively (χ(2) = 12.403, P = 0.002). Univariate analyses failed to identify any prognostic factors for locoregional recurrence in pT3N0 patients. Multivariate analysis showed that the T stage had no effect on locoregional recurrence. The locoregional recurrence rate in patients with pT3N0M0 breast cancer who underwent mastectomy and did not receive postoperative radiotherapy was not higher than that in patients with pT1-2N0M0 breast cancer who received the same treatment, suggesting that routine adjuvant post-operative radiotherapy should not be recommended in this patient population.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Locoregional recurrence‐free survival.
Figure 2
Figure 2
Distant recurrence‐free survival.
Figure 3
Figure 3
Overall survival.
See this image and copyright information in PMC

References

    1. Overgaard M, Hansen PS, Overgaard J et al Postoperative radiotherapy in high‐risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949–55. - PubMed
    1. Overgaard M, Jensen MB, Overgaard J et al Postoperative radiotherapy in high‐risk postmenopausal breast‐cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641–8. - PubMed
    1. Ragaz J, Olivotto IA, Spinelli JJ et al Locoregional radiation therapy in patients with high‐risk breast cancer receiving adjuvant chemotherapy: 20‐year results of the British Columbia randomized trial. J Natl Cancer Inst 2005; 97: 116–26. - PubMed
    1. Recht A, Edge SB, Solin LJ et al Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539–69. - PubMed
    1. Ceilley E, Jagsi R, Goldberg S et al Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 2005; 61: 365–73. - PubMed

MeSH terms